[JLABS Family] LiveStorm
JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1
January 25, 2018 from 11:00 AM to 14:00 PM (EDT)
$10 - $35
Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Toronto. JLABS @ Toronto officially has been open for a year and a half and currently has 45+ companies with several more in the pipeline. Five companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.
Thursday January 25th, 2017
10:00AM | Registration
10:30AM | Presentations
11:45PM | Q&A
12:00PM | Lunch & Networking
1:00pm | Program Close
* Light food and beverage provided
Acorn Biolabs Inc. read more»
Cyclica Inc. read more»
Mediphage Bioceuticals read more»
Qing Bile Therapeutics Inc. read more»
SYNG Pharma read more»
Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.
JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, ON M5G 0B7
Presenting Companies' Descriptions:
Acorn Biolabs Inc.
People’s own cells and genomes are becoming the foundation of current and future biomedical therapeutics. Aged cells, however, are highly mutated, deteriorated versions of our current cells. Acorn Biolabs has developed a mail-in non-invasive cell collection kit to cryopreserve and sequence people’s cells, empowering them with information today and preparing them for future therapeutics.
Cyclica’s cloud-based Software-as-a-Service platform, Ligand Express™ combines an innovative structure-based proteome-wide screening technology with artificial intelligence to help scientists discover better medicines by uncovering and explaining the polypharmacological effects of small molecule therapeutics.
Mediphage Bioceuticals (MB) is a University of Waterloo spin-off biotechnology company that focuses on the manipulation of bacteriophages and prokaryotic genetics to develop new therapeutic platforms that confer safe, effective and scalable treatment solutions for human disease.
Qing Bile Therapeutics Inc.
Qing Bile Therapeutics Inc. is created in 2015 to develop and commercialize effective pharmaceuticals based on its unique proprietary Tetrahydroxylated Bile Acid (THBA) Platform to treat bile acid imbalance metabolic diseases. There is tremendous untapped potential to intervene, to produce therapeutics for a host of unmet medical needs.
A peptide-drug company developing first-in-class therapies and diagnostics for endometriosis and prostate cancer.